Drugs / FTD-TPI
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT06563986 Background | Jun 2024 → Jan 2028 expected | colorectal cancer | UMC Utrecht | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FTD-TPI | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06563986 ↗ |
| Known as | trifluridine/tipiracil | “In the same patient population, trifluridine/tipiracil (FTD-TPI) and bevacizumab lead to disease control and overall survival benefit and may be a radiosensitizer.” NCT06563986 ↗ |
| Route | Oral | “Days 1-5: oral intake of FTD-TPI and bevacizumab IV infusion on day 1” NCT06563986 ↗ |